

Date: 06th August, 2024

To, National Stock Exchange of India Limited Exchange Plaza, C-1 Block G, Bandra Kurla Complex Bandra [E], Mumbai – 400051 NSE Scrip Symbol: KRONOX	To, BSE Limited 25 th Floor, Phiroze Jeejeebhoy Towers, Dalal Street, Fort, Mumbai - 400 001 BSE Scrip Code: 544187
---	--


Subject: Outcome of Meeting of Board of Directors

Dear Sir/Madam,

We would like to inform you that pursuant to Regulation 30, Regulation 33 as well as other applicable regulations, if any, of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('LODR'), the Board of Directors of the Company at its meeting held on Tuesday, August 06, 2024, inter alia, have approved the following matters:

1. The Unaudited standalone financial results for the quarter ended June 30, 2024. A copy of duly signed audited financial results along with Limited Review Report is enclosed.
2. Convening of 15th Annual General Meeting (AGM) of the Company on Friday, August 30, 2024.
3. Pursuant to the provisions of Section 91 of the Companies Act, 2013, ('the Act') read with Rule 10(1) of Companies (Management and Administration) Rules 2014 ('the Rules') and Regulation 42 of the LODR, the Board of Directors has decided to close its Register of Members and Share Transfer Books from Saturday, August 24, 2024, to Friday, August 30, 2024, (both days inclusive) for the purpose of 15th Annual General Meeting and determining entitlement of the members of the final dividend (if declared at the AGM). Kindly display the same on your respective websites.

SYMBOL	Type of Security	Book Closure. (Both Days Inclusive)		Record Date	Purpose
		From	To		
BSE-544187	Equity Shares	Saturday, 24th August, 2024	Friday, 30th August, 2024	Friday, 23 rd August, 2024	15th AGM & Final Dividend (if Declared at AGM)
NSE- KRONOX					



KRONOX LAB SCIENCES LIMITED

Corporate Office Address : Block No. 284, Village : Dabhasa, Taluka : Padra, Dist. : Vadodra, Gujarat State - 391 440.

Registered Office Address : Block No. 353, Village : Ekalbara, Taluka : Padra, Dist. : Vadodra, Gujarat State - 391 440.

Phone No. : +91 2662 244077, 244088

CIN : U24117GJ2008PLC055460

Email : info@kronoxlabsciences.com,

Website : www.kronoxlabsciences.com


CIN : U24117GJ2008PLC055460

4. Appointment of M/s. Devesh Pathak & Associates, Practising Company Secretaries, Vadodara as Secretarial Auditor for the year 2024-25.
5. Appointment of M/s. Jaimin & Associates, Chartered Accountants, Vadodara as Internal Auditors for the year 2024-25.

The Board Meeting commenced at 11:30 A.M. and concluded at 12:45 P.M. today

This is for your information and further dissemination.

Thanking you,
Yours Faithfully
For **KRONOX Lab Sciences Limited**



Nikhil Goswami
Company Secretary & Compliance Officer
Membership No. A68272



KRONOX LAB SCIENCES LIMITED

Corporate Office Address : Block No. 284, Village : Dabhasa, Taluka : Padra, Dist. : Vadodara, Gujarat State - 391 440.
Registered Office Address : Block No. 353, Village : Ekalbara, Taluka : Padra, Dist. : Vadodara, Gujarat State - 391 440.
Phone No. : +91 2662 244077, 244088
Email : info@kronoxlabsciences.com,
CIN : U24117GJ2008PLC055460
Webside : www.kronoxlabsciences.com
CIN : L24117GJ2008PLC055460

KRONOX LAB SCIENCES LIMITED

Regd. Office: Block No. 353, Village: Ekalbara, Taluka: Padra, District: Vadodara 391440 Gujarat
 email: cs@kronoxlabsciences.com ; CIN: L24117GJ2008PLC055460
 Quarterly & Year ended Financial Result by Companies Other than Banks
Unaudited Financial Results for the Quarter ended 30.06.2024 (Rs In Lakhs)

Sr.No	Particulars	Quarter Ended			Year Ended
		30.06.2024	30.06.2023	31.03.2024	31.03.2024
		Unaudited	Unaudited	Audited	Audited
	INCOME FROM OPERATION				
1	Revenue from Operation	2,519.26	2,595.23	2,217.64	8,986.24
2	Other Income	43.22	24.28	82.60	157.79
3	Total Income	2,562.48	2,619.51	2,300.24	9,144.03
	EXPENSES				
a	Cost of Materials Consumed	1,229.08	1,176.47	1,209.36	4,489.37
b	Changes in Inventories of Finished Goods, Work in progress and Stock-In-Trade	108.26	168.44	(161.43)	96.38
c	Employee Benefits expenses	117.17	181.93	121.26	622.85
d	Finance Costs	-	-	-	-
e	Depreciation and amortisation Expenses	33.24	31.84	28.89	128.88
f	Other Expenses	243.94	216.64	262.57	945.75
	TOTAL EXPENSES	1,731.69	1,775.33	1,460.66	6,283.22
5	Profit before Tax	830.79	844.18	839.58	2,860.81
6	Tax Expenses				
a	Current Tax	216.66	217.59	227.11	734.88
b	Deferred Tax	(0.89)	(11.46)	24.27	(9.20)
c	Tax Expenses/Refunds relating to prior years	-	-	-	-
7	Profit after Tax for the Period	615.02	638.05	588.21	2,135.13
8	Other Comprehensive Income				
a	Item that will not be reclassified to profit or loss				
	(i) Defined benefit Plan liability/assets	4.94	7.10	7.60	25.51
	(ii) Tax Impact on above item	(1.24)	(8.84)	(0.72)	(5.23)
b	Item that will be reclassified to profit or loss				
	(i) Exchange difference arising on translation of foreign operations	-	-	-	-
c	Exceptional Items	-	-	-	-
9	Total Comprehensive Income for the period	618.72	636.31	595.09	2,155.41
10	Paid up share capital(FV Rs.10/- per share.)	3710.4	3710.4	3710.4	3710.4
11	Earning per equity share (In Rupees) (F V Rs.10/- per share) (Basic & Dilluted)	1.67	1.71	1.60	5.81

Notes:

- 1 The above Unaudited results have been prepared in accordance with Indian Accounting Standard (IND AS) notified under section 133 of the companies Act, 2013, read together with relevant rules issued there under and other accounting principles generally accepted in India.
- 2 The above results, have been reviewed by the Statutory Auditors, recommended by the Audit Committee and Approved by the Board of Directors in their meeting held on 06th August, 2024.
- 3 The Company is having only one reportable segment under Ind As-108 on "Operating Segments" i.e. manufacturing of High Purity Speciality Fine chemical.
- 4 The previous quarters'/years' figures have been regrouped/rearranged wherever necessary to make it comparable with the current quarter/year.
- 5 The Company has completed its Initial Public Offer (IPO) being 100% offer for sale of 95,70,000 equity shares of face value of INR 10 each at and issue price of INR 136 per share. (including premium of Rs.126 per share). Pursuant to the IPO, the equity shares of the Company were listed on National Stock Exchange of India Limited (NSE) and BSE Limited (BSE) on 10th June, 2024.


Date: 06/08/2024
Place: Vadodara



For and on behalf of the Board of
KRONOX LAB SCIENCES LIMITED

Jagindersingh Jaswal

Jagindersingh Jaswal
Chairman & Managing Director
DIN: 02385809



Independent Auditor's Review Report on the Quarterly Unaudited Standalone Financial Results of the KRONOX LAB SCIENCES LIMITED Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

Review report to


**The Board of Directors
KRONOX LAB SCIENCES LIMITED**

We have reviewed the accompanying statement of unaudited financial results of **KRONOX LAB SCIENCES LIMITED** for the quarter ended 30th June 2024 and year to date from 1st April, 2024 to 30th June, 2024 ("the Statement"). attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").

The company's Management is responsible for the preparation of the statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The Statement has been approved by the Company's Board of Directors. Our responsibility is to express a conclusion on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and



Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Other Matters

The comparative financial results of the Company for the quarter ended June 30, 2023 and for the quarter ended March 31, 2024, being the balancing figure between audited figures for the year ended March 31, 2024 and unaudited year to date figures up to the quarter ended December 31, 2023, which have been prepared solely based on the information complied by the management. However, they have not been subject to limited review by us.

Our report on the Statement is not modified in respect of these matters.

For Mahesh Udhwani & Associates
Chartered Accountants
FRN :129738W

M. A. Udhwani

Mahesh Udhwani

Partner

M.No.047328

UDIN: 24047328BJZYQF1571

Place: Vadodara

Date : 06/08/2024

